QUOTE AND NEWS
StreetInsider.com  Jul 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Palatin+Technologies+%28PTN%29+Receives+USPTO+Notice+of+Allowance+for+%27422+Application/9647370.html for the full story.
SeekingAlpha  May 13  Comment 
Palatin Technologies, Inc (PTN) Q3 2014 Earnings Conference Call May 13, 2014 11:00 AM ET Executives Carl Spana - President and CEO Steve Wills - CFO, COO and EVP Dr. Jeffrey Edelson - CMO Analysts Charles Duncan -...
DailyFinance  Apr 10  Comment 
MALVERN, PA -- (Marketwired) -- 04/10/14 -- Vishay Intertechnology, Inc. (NYSE: VSH) today announced that it has extended the power rating of PTN series precision surface-mount thin film chip resistors in the 2512 case size to 2 W. Built using a...
Benzinga  Feb 24  Comment 
Palatin Technologies (NYSE: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual...
SeekingAlpha  Feb 18  Comment 
Palatin Technologies, Inc. (PTN) F2Q2014 Earnings Conference Call February 18, 2014 11:00 AM ET Executives Carl Spana - President and CEO Steve Wills - CFO, COO and EVP Dr. Jeffrey Edelson - CMO Analysts Charles Duncan -...
Benzinga  Jan 13  Comment 
Palatin Technologies (NYSE MKT: PTN) announced today that in view of the unusual market activity in common stock of the Company on Monday, January 13, 2014, the NYSE MKT (the "Exchange") has contacted the Company in accordance with the Exchange's...
DailyFinance  Nov 25  Comment 
Clinical Operations experts from Palatin Technologies, Inc. (NYSE MKT: PTN) and PHT Corporation will present on the effective use of eCOA Systems for clinical research on Female Sexual Dysfunction (FSD) at the Managing ...
StreetInsider.com  Nov 14  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Palatin+Technologies%2C+Inc.+%28PTN%29+Post+Slightly+Smaller+Q1+Loss/8885483.html for the full story.
Cloud Computing  Oct 21  Comment 
BANGALORE, India , Oct. 21, 2013 /PRNewswire/ -- Tejas Networks Ltd. announces the latest release of the award winning XTN TJ1400 series for Packet Transport Networks (PTN).  PTN Release 2.0 significantly increases the capabilities of the XTN...




 
TOP CONTRIBUTORS

Palatin Technologies (AMEX:PTN) is a biopharmaceutical company dedicated to the development of proprietary peptide, peptide mimetic and small molecule agonist compounds with a focus on therapeutics that modulate melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, ischemia and reperfusion injury, hemorrhagic shock and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of heart failure, hypertension and other cardiovascular diseases.

Palatin has collaborations with industry leaders AstraZeneca (NYSE:AZN) and the Mallinckrodt division of Covidien (NYSE:COV).

Product Portfolio PL-3994, a peptidomimetic natriuretic peptide receptor A agonist, for treatment of heart failure, including congestive heart failure. Bremelanotide, a peptide melanocortin receptor agonist, for prevention of organ damage secondary to cardiac surgery and related indications. PL-3994, a peptidomimetic natriuretic peptide receptor A agonist, for treatment of difficult-to-control hypertension, including dialysis patients with hypertension. PL-6983, a peptide melanocortin-4 receptor agonist, for treatment of female sexual dysfunction. Ongoing research collaboration and global license with AstraZeneca AB on melanocortin receptor-based compounds for treating obesity and related metabolic syndrome. NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection, is the subject of a strategic collaboration agreement with the Mallinckrodt division of Covidien. All ongoing clinical trials and regulatory approvals of NeutroSpec have been suspended while the Company and Mallinckrodt evaluate future development and marketing activities involving NeutroSpec.

Carl Spana, Ph.D., President and Chief Executive Officer Dr. Spana, co-founder of Palatin, has served as president and chief executive officer since 2000. He has been a director of Palatin since 1996 and has been a director of Palatin’s wholly-owned subsidiary, RhoMed Incorporated, since 1995. From 1996 to 2000, Dr. Spana served as an executive vice president and chief technical officer of Palatin.

From 1993 to 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From 1991 to 1993, Dr. Spana was a research associate at Bristol-Myers Squibb, a publicly traded pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana is a director of AVAX Technologies, Inc., a publicly traded medical technology company, and a director of Curalogic A/S, a Danish life science company publicly traded on the Copenhagen Stock Exchange.

Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.





References

http://www.palatin.com/aboutpalatin/overview.asp

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki